Trial reportMycopathologia2011
Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis.
Trial report in Mycopathologia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 67 citations in OpenAlex.
- In Vitro Antifungal Drug Susceptibility of Feline Sporothrix schenckii Complex Isolates, Thailand, 2023-2025.Emerging infectious diseases · 2026Article
- Current Insights intoJournal of fungi (Basel, Switzerland) · 2025Article
- Sporotrichosis: an overview of the neglected disease reported worldwide in the last five years.Revista da Sociedade Brasileira de Medicina Tropical · 2025Review
- Sporotrichosis caused byMedical mycology case reports · 2024Article
- Whole transcriptome sequencing for revealing the pathogenesis of sporotrichosis caused by Sporothrix globosa.Scientific reports · 2024Article
- Invasive fungal infections and oomycoses in cats 2. Antifungal therapy.Journal of feline medicine and surgery · 2024Review
- Article
- Sporotrichosis in Older Adults: A Cohort Study of 911 Patients from a Hyperendemic Area of Zoonotic Transmission in Rio de Janeiro, Brazil.Journal of fungi (Basel, Switzerland) · 2023Article
- Current Progress on Epidemiology, Diagnosis, and Treatment of Sporotrichosis and Their Future Trends.Journal of fungi (Basel, Switzerland) · 2022Review
- Pulmonary Sporotrichosis Caused byJournal of fungi (Basel, Switzerland) · 2022Article
- Severe Sporotrichosis Treated with Amphotericin B: A 20-Year Cohort Study in an Endemic Area of Zoonotic Transmission.Journal of fungi (Basel, Switzerland) · 2022Article
- Sporotrichosis Caused by Non-Wild TypeFrontiers in cellular and infection microbiology · 2022Article
- Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology.The Lancet. Infectious diseases · 2021Review
- In vitro antifungal susceptibility of Sporothrix globosa isolates from Jilin Province, northeastern China: comparison of yeast and mycelial phases.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021Article
- Guideline for the management of feline sporotrichosis caused by Sporothrix brasiliensis and literature revision.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021Review
- A One Health Approach to CombattingJournal of fungi (Basel, Switzerland) · 2020Review
- Successful Treatment of Canine Sporotrichosis with Terbinafine: Case Reports and Literature Review.Mycopathologia · 2018Review
- Sporotrichosis byMedical mycology case reports · 2018Article
- Multicenter, International Study of MIC/MEC Distributions for Definition of Epidemiological Cutoff Values for Sporothrix Species Identified by Molecular Methods.Antimicrobial agents and chemotherapy · 2017Article
- Minimal inhibitory concentration distributions and epidemiological cutoff values of five antifungal agents against Sporothrix brasiliensis.Memorias do Instituto Oswaldo Cruz · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledItraconazole is currently used for the treatment of cutaneous sporotrichosis. Terbinafine at a daily dose of 250 mg has been successfully applied to the treatment of cutaneous sporotrichosis.
objectiveTo compare the efficacy of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. MATERIALS AND
methodsA bidirectional cohort study was conducted on 55 patients receiving 250 mg/day terbinafine and 249 patients receiving 100 mg/day itraconazole. The latter patients were matched for age and clinical form to the terbinafine group at a ratio of 5:1. Sporothrix schenckii was isolated by culture from all patients (age range: 18-70 years), who were submitted to the standard care protocol consisting of clinical and laboratory evaluation and periodic visits.
resultsCure was observed in 51 (92.7%) patients of the terbinafine group and 229 (92%) of the itraconazole group within a similar mean period of time (11.5 and 11.8 weeks, respectively). An increase in the terbinafine dose to 500 mg was necessary in two patients due to the lack of a response, and one patient presented recurrence. In the itraconazole group, two patients required a dose increase and three presented recurrence. Adverse events were equally frequent among patients receiving terbinafine (n = 4, 7.3%) and itraconazole (n = 19, 7.6%) and were generally mild without the need for drug discontinuation, except for two patients of the itraconazole group.
conclusionTerbinafine administered at a daily dose of 250 mg is an effective and well-tolerated option for the treatment of cutaneous sporotrichosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.